Cellular Therapy for Fanconi Anemia: The Past, Present, and Future

被引:16
|
作者
MacMillan, Margaret L. [1 ]
Hughes, Mark R. [2 ]
Agarwal, Suneet [3 ,4 ,5 ,6 ,7 ]
Daley, George Q. [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词
BONE-MARROW-TRANSPLANTATION; PLURIPOTENT STEM-CELLS; APLASTIC-ANEMIA; DONORS; CYCLOPHOSPHAMIDE; IRRADIATION; DISEASE; BLOOD; ENGRAFTMENT; GENERATION;
D O I
10.1016/j.bbmt.2010.11.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 50 条
  • [31] Plasmablastic Lymphoma: Past, Present, and Future
    Kaur, Supreet
    Kollimuttathuillam, Sudarsan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (09) : e253 - e259
  • [32] Focusing on the past, present, and future of hepatology
    Shouval, Daniel
    Friedman, Scott L.
    JOURNAL OF HEPATOLOGY, 2014, 61 (06) : 1196 - 1198
  • [33] Normal saline: Past, present, and future
    Liu, Xinwen
    Lu, Mengkai
    SCIENCE PROGRESS, 2023, 106 (02)
  • [34] Past, present and future of immunology in Mainz
    Waisman, Ari
    Hoevelmeyer, Nadine
    Diefenbach, Andreas
    Schuppan, Detlef
    Reddehase, Mathhias J.
    Kleinert, Hartmut
    Kaina, Bernd
    Grabbe, Stephan
    Galle, Peter R.
    Theobald, Matthias
    Zipp, Frauke
    Sahin, Ugur
    Tuereci, Oeslem
    Kreiter, Sebastian
    Langguth, Peter
    Decker, Heinz
    van Zandbergen, Ger
    Schild, Hansjoerg
    CELLULAR IMMUNOLOGY, 2016, 308 : 1 - 6
  • [35] Aging and Medications: Past, Present, Future
    Schwartz, J. B.
    Abernethy, D. R.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (01) : 3 - 10
  • [36] Frontotemporal dementia: Past, present, and future
    Ulugut, Hulya
    Pijnenburg, Yolande A. L.
    ALZHEIMERS & DEMENTIA, 2023, 19 (11) : 5253 - 5263
  • [37] The preanalytical phase - Past, present and future
    Cornes, Michael
    ANNALS OF CLINICAL BIOCHEMISTRY, 2020, 57 (01) : 4 - 6
  • [38] Endocrine abnormalities in patients with fanconi anemia
    Giri, Neelam
    Batista, Dalia L.
    Alter, Blanche P.
    Stratakis, Constantine A.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07) : 2624 - 2631
  • [39] Current clinical management of Fanconi anemia
    Smith, Angela R.
    Wagner, John E.
    EXPERT REVIEW OF HEMATOLOGY, 2012, 5 (05) : 513 - 522
  • [40] A Possible Approach for Stem Cell Gene Therapy of Fanconi Anemia
    Song, Liting
    CURRENT GENE THERAPY, 2009, 9 (01) : 26 - 32